Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Beta-glucan Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Tolerability of Oat Fiber (BG-OS) in Healthy Individuals

NCT06739941
View directory record Official record
Conditions
Digestive Health, Metabolic Health
Interventions
Oat fiber (BG-OS)
Other
Lead sponsor
One Bio Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease

NCT01747135
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
VTS-270
Drug
Lead sponsor
Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company
Industry
Eligibility
2 Years to 25 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 23, 2026, 10:35 PM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1

NCT04860960
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-beta-cyclodextrin, Placebo
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Oakland, California • Jacksonville, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 23, 2026, 10:35 PM EDT
Recruiting Not applicable Interventional

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

NCT04513028
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
Beta-Glucan
Dietary Supplement
Lead sponsor
Kelly McMasters
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional Results available

Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)

NCT00290407
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, Lymphoma, Small Lymphocytic
Interventions
Rituximab, Beta-Glucan
Drug · Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 3 Interventional Results available

Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System

NCT03643562
View directory record Official record
Conditions
Niemann-Pick Type C Disease
Interventions
Adrabetadex
Drug
Lead sponsor
Mandos LLC
Industry
Eligibility
4 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)

NCT04209075
View directory record Official record
Conditions
Diabetes
Interventions
Biomebliss, Metformin, Placebo
Dietary Supplement · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
10 Years to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Not applicable Interventional

MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

NCT03461354
View directory record Official record
Conditions
Mucositis Oral, Head and Neck Cancer
Interventions
MucoLox, Sodium Bicarbonate
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 23, 2026, 10:35 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Determine if Beta Glucan Reduces the Incidence, Duration or Severity of URTIs Among Skiers

NCT05917015
View directory record Official record
Conditions
Upper Respiratory Tract Infections, Mental Stress
Interventions
Treatment, Placebo
Dietary Supplement · Other
Lead sponsor
USANA Health Sciences
Industry
Eligibility
18 Years to 30 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Park City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 4 Interventional Results available

Preadmission Skin Wipe Use for Surgical Site Infection Prophylaxis in Adult Orthopaedic Surgery Patients

NCT03401749
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chlorhexidine Gluconate 2% Wipe, Theraworx Bath Wipes
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 64 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Beta-glucan, Product Claims and Satiety

NCT04740112
View directory record Official record
Conditions
Healthy
Interventions
Foods with beta-glucan from oats and barley
Other
Lead sponsor
General Mills
Industry
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

NCT02939547
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-beta-cyclodextrin
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Oakland, California • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Beta Glucan 500 and Biological Age and Immune Age

NCT07104929
View directory record Official record
Conditions
Aging
Interventions
Beta Glucan
Dietary Supplement
Lead sponsor
OvationLab
Network
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Hot Cereal on Digestive Health in Children

NCT02868515
View directory record Official record
Conditions
Subjective Measures of Digestive Health Post Consumption
Interventions
Hot cereal contain 3 g dietary fiber
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
7 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

NCT01269385
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Interventions
alemtuzumab, rituximab, PGG beta-glucan, flow cytometry, laboratory biomarker analysis, DNA analysis, fluorescence in situ hybridization, polymerase chain reaction, polymorphism analysis, mutation analysis
Biological · Drug · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 1 Interventional

A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT05484011
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
odetiglucan, CDX-1140
Biological
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Two Different Lion's Mane Extracts (Lions Mane Fruiting Body & Lions Mane Fruiting Body With Mycellium) on Cognitive Performance, Subjective Affect, Serum Biomarkers, and Gut Microbiota in Healthy Adults

NCT07405957
View directory record Official record
Conditions
Healthy Adult Females, Healthy Adult Male
Interventions
Lion Mane (Hericium erinaceus) fruiting body extract - Nordic Origin, Lions Mane (Hericium erinaceus) Fruiting body and mycelium, Maltodextrin (Placebo)
Dietary Supplement · Other
Lead sponsor
Applied Food Sciences Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 1 Interventional

(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer

NCT02132403
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
BTH1704, IMPRIME PGG, Gemcitabine
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 23, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

NCT06057948
View directory record Official record
Conditions
Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
Interventions
OPT-821 (QS-21), oral β-glucan
Biological · Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 23, 2026, 10:35 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease

NCT04958642
View directory record Official record
Conditions
Niemann-Pick Disease, Type C
Interventions
Adrabetadex
Drug
Lead sponsor
Mandos LLC
Industry
Eligibility
4 Years to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

NCT00002098
View directory record Official record
Conditions
HIV Infections
Interventions
Lentinan, Didanosine
Drug
Lead sponsor
AJI Pharma USA
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California • Maitland, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

NCT00911560
View directory record Official record
Conditions
Neuroblastoma
Interventions
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH, oral β-glucan
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 23, 2026, 10:35 PM EDT